Prescient Therapeutics LimitedASX: PTX

Interim Durability Analysis of PTX-200 Breast Cancer Study

Dec 10, 2018 at 4:13 AM UTC · Issued by Prescient Therapeutics Limited

Prescient Therapeutics Ltd has released a press release.

View Attachment